Association of Cancer Diagnosis and Therapeutic Stage With Mortality in Pediatric Patients With COVID-19, Prospective Multicenter Cohort Study From Latin America
Authors: Dominguez-Rojas Jesus Ángel , Vásquez-Hoyos Pablo , Pérez-Morales Rodrigo , Monsalve-Quintero Ana María , Mora-Robles Lupe , Diaz-Diaz Alejandro , Torres Silvio Fabio , Castro-Dajer Ángel , Cabanillas-Burgos Lizeth Yuliana , Aguilera-Avendaño Vladimir , Cantillano-Quintero Edwin Mauricio , Camporesi Anna , Agulnik Asya , Mukkada Sheena , Alvarado-Gamarra Giancarlo , Rojas-Soto Ninoska , Mendieta-Zevallos Ana Luisa , Tello-Pezo Mariela Violeta , Vásquez-Ponce Liliana , Lasso-Palomino Rubén Eduardo , Pérez-Arroyave María Camila , Trujillo-Honeysberg Mónica , Mesa-Monsalve Juan Gonzalo , Pardo González Carlos Alberto , López Cubillos Juan Francisco , Gonzalez-Dambrauskas Sebastián , Coronado-Munoz Alvaro 
Published: May 2022

Background

Children with cancer are at risk of critical disease and mortality from COVID-19 infection. In this study, we describe the clinical characteristics of pediatric patients with cancer and COVID-19 from multiple Latin American centers and risk factors associated with mortality in this population.

Methods

This study is a multicenter, prospective cohort study conducted at 12 hospitals from 6 Latin American countries (Argentina, Bolivia, Colombia, Ecuador, Honduras and Peru) from April to November 2021. Patients younger than 14 years of age that had an oncological diagnosis and COVID-19 or multisystemic inflammatory syndrome in children (MIS-C) who were treated in the inpatient setting were included. The primary exposure was the diagnosis and treatment status, and the primary outcome was mortality. We defined “new diagnosis” as patients with no previous diagnosis of cancer, “established diagnosis” as patients with cancer and ongoing treatment and “relapse” as patients with cancer and ongoing treatment that had a prior cancer-free period. A frequentist analysis was performed including a multivariate logistic regression for mortality.

Results

Two hundred and ten patients were included in the study; 30 (14%) died during the study period and 67% of patients who died were admitted to critical care. Demographics were similar in survivors and non-survivors. Patients with low weight for age (&lt;-2SD) had higher mortality (28 vs. 3%, p = 0.019). There was statistically significant difference of mortality between patients with new diagnosis (36.7%), established diagnosis (1.4%) and relapse (60%), (p &lt;0.001). Most patients had hematological cancers (69%) and they had higher mortality (18%) compared to solid tumors (6%, p= 0.032). Patients with concomitant bacterial infections had higher mortality (40%, p = 0.001). MIS-C, respiratory distress, cardiovascular symptoms, altered mental status and acute kidney injury on admission were associated with higher mortality. Acidosis, hypoxemia, lymphocytosis, severe neutropenia, anemia and thrombocytopenia on admission were also associated with mortality. A multivariate logistic regression showed risk factors associated with mortality: concomitant bacterial infection OR 3 95%CI (1.1–8.5), respiratory symptoms OR 5.7 95%CI (1.7–19.4), cardiovascular OR 5.2 95%CI (1.2–14.2), new cancer diagnosis OR 12 95%CI (1.3–102) and relapse OR 25 95%CI (2.9–214).

Conclusion

Our study shows that pediatric patients with new onset diagnosis of cancer and patients with relapse have higher odds of all-cause mortality in the setting of COVID-19. This information would help develop an early identification of patients with cancer and COVID-19 with higher risk of mortality.